We found a bullish thesis on United Therapeutics Corporation in the BioEquity Watch Substack. In this article, we will summarize the bulls thesis on UTHR. Shares of United Therapeutics Corporation were trading at $471.99 on January 15. UTHR’s trailing and forward P/E were 17.89 and 15.15 respectively according to Yahoo Finance.
Phovoir/Shutterstock.com
United Therapeutics Corporation is a commercial-stage biotechnology company built around treprostinil, a prostacyclin analog that drives its leadership in pulmonary arterial hypertension through multiple differentiated delivery platforms, including Tyvaso, Tyvaso DPI, Remodulin and Orenitram. Treprostinil’s mechanism of action enables direct pulmonary vasodilation and United Therapeutics has successfully expanded its utility in PAH and PH-ILD, establishing a long-standing and highly profitable franchise.
The next big value driver is Tyvaso’s expansion into idiopathic pulmonary fibrosis without comorbid pulmonary hypertension, a significantly larger indication with high unmet need. The ex-U.S. Phase 3 trial TETON-2 met its primary endpoint, demonstrating preservation of lung function, suggesting that treprostinil may offer antifibrotic benefits beyond hemodynamic effects. The ongoing TETON-1 study in the US and Canada is the critical catalyst that could support a supplemental NDA and materially expand the company’s addressable market to approximately 100,000 US patients.
Financially, United Therapeutics is exceptionally well positioned, with more than $4 billion in cash and investments, strong operating cash flow exceeding $1.3 billion annually, and no reliance on external financing. This balance sheet strength allows the company to absorb litigation risk, fund R&D, and pursue ambitious long-term organ manufacturing initiatives while maintaining profitability.
While competitive pressure from Liquidia and others may impact near-term dynamics within inhaled treprostinil, United Therapeutics’ multimodal platform, entrenched patient support infrastructure and clinical execution provide significant competitive insulation. With TETON-1 representing a clear inflection point and a downside protected by a strong core franchise, United Therapeutics offers an attractive risk-reward bias for investors willing to underwrite short-term clinical risks.
Previously, we covered a bullish thesis at CRISPR Therapeutics AG (CRSP) by MADD-Scientis in March 2025, which highlighted Casgevy’s commercial potential, early patient acceptance, progress in insurance reimbursement, and a robust gene editing pipeline. CRSP stock has appreciated approximately 32% since our coverage.. United Therapeutics Corporation (UTHR) shares a similar bullish view, but emphasizes the growth of treprostinil’s expansion in idiopathic pulmonary fibrosis and the upcoming TETON-1 trial.